Nama's AI scorecard currently rates Bausch Health Companies Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is BHC's P/E ratio?

Bausch Health Companies trades at a trailing price-to-earnings ratio of 1.7.

When does BHC report earnings?

Bausch Health Companies's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $1.32.

What is the BHC price target?

The median analyst price target from 5 analysts is $8.00, with a range of $7.00 – $10.00.

Is BHC Shariah compliant?

Nama's AAOIFI-style screen reads Bausch Health Companies as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Bausch Health Companies (BHC)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Bausch Health Companies (BHC) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $3.06B, a trailing price-to-earnings ratio of 1.7 and a free-cash-flow yield of 32.4%. Over the most recent reported fiscal year, revenue grew 6.7% and free cash flow per share fell 25.5%. Nama's AI scorecard rates it Hold, 5.6 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Hold · 5.6/10

The sections balance. As of Nov 7, 2026.

Momentum

Lagging · -8.1% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-71.3%

How far the last close sits under the highest price of the past five years.

Market cap	$3.06B
Trailing P/E	1.7
Price / book	—
Price / sales	0.3
FCF yield	32.4%
Dividend yield	—
Gross margin	72.6%
Operating margin	28.2%
Net margin	-7.6%
Revenue growth (YoY)	+6.7%
Revenue growth (3-yr annual)	+8.1%
EPS growth (YoY)	-1.8%
FCF/share growth (YoY)	-25.5%
Beta	0.4
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

BHC earnings

Next report: Feb 17, 2027 (Q4 2026, EPS estimate $1.32). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 28, 2026	$1.77	$1.24	+42.7%	$2.94B
Q2 2026	Jul 29, 2026	$1.26	$1.01	+24.8%	$2.85B
Q1 2026	Apr 29, 2026	$0.78	$0.69	+13.0%	$2.52B
Q4 2025	Feb 18, 2026	$1.10	$1.26	-12.7%	$2.80B

BHC analyst price target

Median target $8.00 from 5 analysts, ranging $7.00 – $10.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live BHC data on Nama Insights →

BHC FAQ

Is BHC a buy?: Nama's AI scorecard currently rates Bausch Health Companies Hold (5.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is BHC's P/E ratio?: Bausch Health Companies trades at a trailing price-to-earnings ratio of 1.7.
When does BHC report earnings?: Bausch Health Companies's next scheduled report is on Feb 17, 2027. Analysts expect EPS of $1.32.
What is the BHC price target?: The median analyst price target from 5 analysts is $8.00, with a range of $7.00 – $10.00.
Is BHC Shariah compliant?: Nama's AAOIFI-style screen reads Bausch Health Companies as Not Shariah Compliant. At least one of the three ratios or the industry test failed.